These results raise the possibility that specific and nontoxic inhibitors of phosphatases may be considered as atherapeutic modality for elevating HbF in patients with β-hemoglobinopathiesas well as for intensifying the Epo response in other forms of anemia. This evidence concerns the gene EPO and anemia (phenotype).